Aida Castellanos
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Aida Castellanos has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
- Xavier Gasull
Neurophysiology Laboratory, Department of Biomedicine, Medical School, Institute of Neurosciences, Universitat de Barcelona, Barcelona, Spain
3 shared publications - Anna Pujol-Coma
Neurophysiology Laboratory, Department of Biomedicine, Medical School, Institute of Neurosciences, Universitat de Barcelona, Barcelona, Spain
2 shared publications - David Soto
Neurophysiology Laboratory, Department of Biomedicine, Faculty of Medicine and Health Sciences, Institute of Neurosciences, University of Barcelona, Barcelona, Spain
2 shared publications - Núria Comes
Molecular Physiology Laboratory, Departament de Bioquímica i Biologia Molecular, Institut de Biomedicina (IBUB), Universitat de Barcelona, Barcelona, Spain
2 shared publications - Ahmed Negm
Université Côte d'Azur, CNRS UMR 7275, IPMC, Valbonne
1 shared publication - Alba Andres-Bilbe
Universitat de Barcelona, Institute of Neurosciences, IDIBAPS
1 shared publication
Latest Publications
- Open Access
- 14 November 2025
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 10 (6)
Efficacy and safety of the Cav2.2 blocker Ziconotide in pain: a meta-analysis and systematic review
Chronic pain remains a significant clinical challenge, especially in refractory cases. Ziconotide, a selective Ca v 2.2 channel blocker, offers an intrathecal approach, but concerns about its safety, potential biases, and impact on opioid consumption persist. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic review and meta-analysis of 23 studies (1,531 participants) to evaluate the efficacy, safety, and secondary outcomes of Ziconotide. Key outcomes were pain intensity reduction, adverse events, and serious adverse events. As secondary outcomes, we assessed changes in opioid consumption. The risk of bias and the certainty of evidence were assessed using risk of bias 2 and Grading of Recommendations, Assessment, Development and Evaluation for randomized controlled trials, ROBINS-I and the Newcastle-Ottawa Scale for observational studies, and the Joanna Briggs Institute checklist for case reports. Publication bias was explored using funnel plot analysis. Ziconotide demonstrated significant pain reduction compared with placebo (mean difference: −22.54, 95% confidence interval [CI]: −36.70 to −8.38, P = 0.002), although heterogeneity was high. Adverse events were frequent (94.9% vs 76.9% in placebo; risk ratio 1.24, 95% CI: 1.09–1.41, P = 0.0008), with serious adverse events reported in 17.85% patients (risk ratio 2.63, 95% CI: 1.52–4.57, P = 0.0006). Secondary outcomes suggested potential reductions in opioid consumption in observational studies, with decreases ranging from 6.4% to 91.5%, though randomized trials showed inconsistent results. Certainty of the evidence was rated as low to moderate. Although Ziconotide shows promise as an intrathecal treatment for refractory pain, its frequent adverse effects, the availability of high-certainty evidence, and inconclusive impact on opioid consumption highlight the need for cautious use. This meta-analysis underscores the need for future research.
- 14 November 2025
- Published by Wolters Kluwer Health in Pain Reports
- Vol. 10 (6)
Open AccessEfficacy and safety of the Cav2.2 blocker Ziconotide in pain: a meta-analysis and systematic review
Chronic pain remains a significant clinical challenge, especially in refractory cases. Ziconotide, a selective Ca v 2.2 channel blocker, offers an intrathecal approach, but concerns about its safety, potential biases, and impact on opioid consumption persist. Following Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines, we conducted a systematic review and meta-analysis of 23 studies (1,531 participants) to evaluate the efficacy, safety, and secondary outcomes of Ziconotide. Key outcomes were pain intensity reduction, adverse events, and serious adverse events. As secondary outcomes, we assessed changes in opioid consumption. The risk of bias and the certainty of evidence were assessed using risk of bias 2 and Grading of Recommendations, Assessment, Development and Evaluation for randomized controlled trials, ROBINS-I and the Newcastle-Ottawa Scale for observational studies, and the Joanna Briggs Institute checklist for case reports. Publication bias was explored using funnel plot analysis. Ziconotide demonstrated significant pain reduction compared with placebo (mean difference: −22.54, 95% confidence interval [CI]: −36.70 to −8.38, P = 0.002), although heterogeneity was high. Adverse events were frequent (94.9% vs 76.9% in placebo; risk ratio 1.24, 95% CI: 1.09–1.41, P = 0.0008), with serious adverse events reported in 17.85% patients (risk ratio 2.63, 95% CI: 1.52–4.57, P = 0.0006). Secondary outcomes suggested potential reductions in opioid consumption in observational studies, with decreases ranging from 6.4% to 91.5%, though randomized trials showed inconsistent results. Certainty of the evidence was rated as low to moderate. Although Ziconotide shows promise as an intrathecal treatment for refractory pain, its frequent adverse effects, the availability of high-certainty evidence, and inconclusive impact on opioid consumption highlight the need for cautious use. This meta-analysis underscores the need for future research.
- Open Access
- 9 October 2023
- Published by MDPI AG in Preprints.org
A Manifesto in Defense of Pain Complexity: A Critical Review of Essential Insights in Pain Neuroscience
Chronic pain has increasingly become a significant health challenge, not just as a symptomatic manifestation but also as a pathological condition with profound socioeconomic implications. Despite the expansion of medical interventions, the prevalence of chronic pain remains remarkably persistent, prompting a turn towards non-pharmacological treatments, such as therapeutic education, exercise and cognitive-behavioral therapy. With the advent of cognitive neuroscience, pain is often presented as a primary output derived from the brain, aligning with Engel's Biopsychosocial Model which views disease not solely from a biological perspective but also considering psychological and social factors. This paradigm shift, brings forward potential misconceptions and over-simplifications. The current review delves into the intricacies of nociception and pain perception. It questions long-standing beliefs like the cerebral-centric view of pain, the forgotten role of the peripheral nervous system in pain chronification, misconceptions around central sensitization syndromes, the controversy about the existence of a dedicated pain neuromatrix, the consciousness of the pain experience and the possible oversight of factors beyond the nervous system. In re-evaluating these aspects, the review emphasizes the critical need for understanding the complexity of pain, urging the scientific and clinical community to move beyond reductionist perspectives and consider the multifaceted nature of this phenomenon.
- 9 October 2023
- Published by MDPI AG in Preprints.org
Open AccessA Manifesto in Defense of Pain Complexity: A Critical Review of Essential Insights in Pain Neuroscience
Chronic pain has increasingly become a significant health challenge, not just as a symptomatic manifestation but also as a pathological condition with profound socioeconomic implications. Despite the expansion of medical interventions, the prevalence of chronic pain remains remarkably persistent, prompting a turn towards non-pharmacological treatments, such as therapeutic education, exercise and cognitive-behavioral therapy. With the advent of cognitive neuroscience, pain is often presented as a primary output derived from the brain, aligning with Engel's Biopsychosocial Model which views disease not solely from a biological perspective but also considering psychological and social factors. This paradigm shift, brings forward potential misconceptions and over-simplifications. The current review delves into the intricacies of nociception and pain perception. It questions long-standing beliefs like the cerebral-centric view of pain, the forgotten role of the peripheral nervous system in pain chronification, misconceptions around central sensitization syndromes, the controversy about the existence of a dedicated pain neuromatrix, the consciousness of the pain experience and the possible oversight of factors beyond the nervous system. In re-evaluating these aspects, the review emphasizes the critical need for understanding the complexity of pain, urging the scientific and clinical community to move beyond reductionist perspectives and consider the multifaceted nature of this phenomenon.
- Open Access
- 23 July 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (15) , 5206
The Background K+ Channel TRESK in Sensory Physiology and Pain
TRESK belongs to the K2P family of potassium channels, also known as background or leak potassium channels due to their biophysical properties and their role regulating membrane potential of cells. Several studies to date have highlighted the role of TRESK in regulating the excitability of specific subtypes of sensory neurons. These findings suggest TRESK could be involved in pain sensitivity. Here, we review the different evidence available that involves the channel in pain and sensory perception, from studies knocking out the channel or overexpressing it to identified mutations that link the channel to migraine pain. In addition, the therapeutic possibilities are discussed, as targeting the channel seems an interesting therapeutic approach to reduce nociceptor activation and to decrease pain.
- 23 July 2020
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 21 (15) , 5206
Open AccessThe Background K+ Channel TRESK in Sensory Physiology and Pain
TRESK belongs to the K2P family of potassium channels, also known as background or leak potassium channels due to their biophysical properties and their role regulating membrane potential of cells. Several studies to date have highlighted the role of TRESK in regulating the excitability of specific subtypes of sensory neurons. These findings suggest TRESK could be involved in pain sensitivity. Here, we review the different evidence available that involves the channel in pain and sensory perception, from studies knocking out the channel or overexpressing it to identified mutations that link the channel to migraine pain. In addition, the therapeutic possibilities are discussed, as targeting the channel seems an interesting therapeutic approach to reduce nociceptor activation and to decrease pain.
- Open Access
TRESK background K + channel deletion selectively uncovers enhanced mechanical and cold sensitivity
Changes in TRESK K + channel expression/function enhance sensory neurons excitability, but its role in somatosensory perception and nociception is poorly understood. We show that TRESK regulates the sensitivity to mechanical and cold stimuli but not the perception of heat. TRESK knockout mice nociceptive neurons present an enhanced excitability; skin nociceptive C-fibers show an increased activation by lower intensity cold or mechanical stimulation and mice lacking TRESK present mechanical and cold hypersensitivity. TRESK is also involved in osmotic pain and in early phases of formalin-induced inflammatory pain, but not in the development of mechanical and heat hyperalgesia during chronic pain. In contrast, mice lacking TRESK present cold allodynia that is not further enhanced by oxaliplatin. In summary, genetic removal of TRESK uncovers enhanced mechanical and cold sensitivity, indicating that it regulates the excitability of specific neuronal subpopulations involved in mechanosensitivity and cold-sensing, acting as a brake to prevent activation by low-intensity stimuli.
Open AccessTRESK background K + channel deletion selectively uncovers enhanced mechanical and cold sensitivity
Changes in TRESK K + channel expression/function enhance sensory neurons excitability, but its role in somatosensory perception and nociception is poorly understood. We show that TRESK regulates the sensitivity to mechanical and cold stimuli but not the perception of heat. TRESK knockout mice nociceptive neurons present an enhanced excitability; skin nociceptive C-fibers show an increased activation by lower intensity cold or mechanical stimulation and mice lacking TRESK present mechanical and cold hypersensitivity. TRESK is also involved in osmotic pain and in early phases of formalin-induced inflammatory pain, but not in the development of mechanical and heat hyperalgesia during chronic pain. In contrast, mice lacking TRESK present cold allodynia that is not further enhanced by oxaliplatin. In summary, genetic removal of TRESK uncovers enhanced mechanical and cold sensitivity, indicating that it regulates the excitability of specific neuronal subpopulations involved in mechanosensitivity and cold-sensing, acting as a brake to prevent activation by low-intensity stimuli.